InspireMD vs Nexgel
Nexgel reported revenue of $11 million in fiscal 2025, 1.3 times InspireMD's $9 million in fiscal 2025. InspireMD's revenue grew 28.1% in its latest year, and Nexgel's grew 31.5%. InspireMD had an operating margin of -552.6%, against -29.4% at Nexgel. Free cash flow was −$37 million at InspireMD and −$1 million at Nexgel.
Side by side
| InspireMD | Nexgel | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $9M | $11M |
| Revenue growth | 28.1% | 31.5% |
| Revenue growth a year, last 5 years | 29.2% | 74.7% |
| Gross margin | 29.5% | 39.5% |
| Operating margin | −552.6% | −29.4% |
| Net margin | −543.3% | −26.3% |
| Free cash flow | −$37M | −$1M |
| Free cash flow margin | −409.5% | −12.1% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 53.4% | 20.6% |
| Last close | $0.62 | $3.35 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $420,805, sold $126,869 | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
InspireMDNexgel
Operating margin
Percent of revenue
InspireMDNexgel
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InspireMDNexgel